| PubChem CID | Drug (INN) | Original Targets (Gene Symbol) | Original Indications |
|---|---|---|---|
| 5566 | trifluoperazine | ADCY1, ADCY3, ADCY4, ADCY6, ADCY8, ADCY9, ADRA1A, ANXA10, ANXA13, ANXA2, ANXA3, ANXA5, ANXA6, CALM1, CALY, DRD2, DRD4, DRD5, F2, FDPS, GRK7, LTB4R, MYH1, MYH2, MYH4, MYH7B, MYL1, MYL12A, MYL2, MYL7, MYL9, MYLK, MYO15A, MYO18B, MYO1C, MYO1D, MYO1E, MYO3A, MYO3B, MYO5B, MYO5C, NDUFAF3, NDUFS5, S100A4, SLC1A5, SLC5A11, SLC7A5, TNNC1, TNNI3, TNNT2 | Antipsychotic Agents, Antiemetics, Alcoholic Intoxication, Chronic, Bipolar Disorder, Catatonia, Hallucinations, Psychotic Disorders, Schizophrenia, Paranoid Schizophrenia, Brain Injuries, Mental deficiency, Alcoholism, Alcohol abuse, Bipolar disorder, Bipolar I disorder, Hallucination, Psychotic disorder, Schizophrenia, paranoid type, Brain injury |
| Drug Name (INN) |
Predicted Drug Target (Uniprot AC) |
Target Prediction Score (Range: 0~1) |
Binding or Not (Positive binding: 1) |
Novel Positives (Novel candidate: 1) |
|---|---|---|---|---|
| trifluoperazine | GPR87 (Q9BY21) | 0.0781 | 0 | - |
| trifluoperazine | CYP3A43 (Q9HB55) | 0.0779 | 0 | - |
| trifluoperazine | ASL (P04424) | 0.0779 | 0 | - |
| trifluoperazine | NDUFAF4 (Q9P032) | 0.0777 | 0 | - |
| trifluoperazine | SDHD (O14521) | 0.0777 | 0 | - |
| trifluoperazine | CACNG1 (Q06432) | 0.0776 | 0 | - |
| trifluoperazine | GABRG1 (Q8N1C3) | 0.0776 | 0 | - |
| trifluoperazine | KLKB1 (P03952) | 0.0776 | 0 | - |
| trifluoperazine | Q8K4Z4 | 0.0775 | 0 | - |
| trifluoperazine | CRKL (P46109) | 0.0775 | 0 | - |
| trifluoperazine | CCNA1 (P78396) | 0.0775 | 0 | - |
| trifluoperazine | ESR2 (Q92731) | 0.0774 | 0 | - |
| trifluoperazine | CHRNA2 (Q15822) | 0.0774 | 0 | - |
| trifluoperazine | PRDX1 (Q06830) | 0.0774 | 0 | - |
| trifluoperazine | GABRQ (Q9UN88) | 0.0774 | 0 | - |
| trifluoperazine | EPOR (P19235) | 0.0773 | 0 | - |
| trifluoperazine | CHRM3 (P20309) | 0.0773 | 0 | - |
| trifluoperazine | P13745 | 0.0772 | 0 | - |
| trifluoperazine | BCAT2 (O15382) | 0.0772 | 0 | - |
| trifluoperazine | CA5A (P35218) | 0.0771 | 0 | - |
| trifluoperazine | TUBA1C (Q9BQE3) | 0.0771 | 0 | - |
| trifluoperazine | RB1 (P06400) | 0.0771 | 0 | - |
| trifluoperazine | IL17C (Q9P0M4) | 0.077 | 0 | - |
| trifluoperazine | P03277 | 0.0767 | 0 | - |
| trifluoperazine | CYP2B6 (P20813) | 0.0767 | 0 | - |
| trifluoperazine | LPO (P22079) | 0.0767 | 0 | - |
| trifluoperazine | Q9WV26 | 0.0767 | 0 | - |
| trifluoperazine | P05042 | 0.0766 | 0 | - |
| trifluoperazine | LCN1 (P31025) | 0.0766 | 0 | - |
| trifluoperazine | PKD2L1 (Q9P0L9) | 0.0765 | 0 | - |
| trifluoperazine | RAMP3 (O60896) | 0.0763 | 0 | - |
| trifluoperazine | GABRD (O14764) | 0.0762 | 0 | - |
| trifluoperazine | MMP3 (P08254) | 0.0762 | 0 | - |
| trifluoperazine | TUBB3 (Q13509) | 0.0762 | 0 | - |
| trifluoperazine | STMN4 (Q9H169) | 0.0762 | 0 | - |
| trifluoperazine | CYP2U1 (Q7Z449) | 0.0761 | 0 | - |
| trifluoperazine | O19045 | 0.076 | 0 | - |
| trifluoperazine | Q9Z8T8 | 0.076 | 0 | - |
| trifluoperazine | PTGS2 (P35354) | 0.076 | 0 | - |
| trifluoperazine | PSMB10 (P40306) | 0.0759 | 0 | - |
| trifluoperazine | HTR1E (P28566) | 0.0759 | 0 | - |
| trifluoperazine | CEACAM3 (P40198) | 0.0759 | 0 | - |
| trifluoperazine | CTSD (P07339) | 0.0758 | 0 | - |
| trifluoperazine | P40030 | 0.0757 | 0 | - |
| trifluoperazine | PRKD3 (O94806) | 0.0754 | 0 | - |
| trifluoperazine | CCNE2 (O96020) | 0.0753 | 0 | - |
| trifluoperazine | IFNA7 (P01567) | 0.0753 | 0 | - |
| trifluoperazine | CYP46A1 (Q9Y6A2) | 0.0753 | 0 | - |
| trifluoperazine | TUBB4A (P04350) | 0.0752 | 0 | - |
| trifluoperazine | CATSPER3 (Q86XQ3) | 0.0752 | 0 | - |
| Drug (INN) |
Drug Mechanism (Gene ontology) |
Mechanism Score (Range: 0~1) |
Positive or not (Positive: 1) |
|---|---|---|---|
| trifluoperazine | GO:0006281 DNA repair | 1 | 1 |
| trifluoperazine | GO:0031570 DNA integrity checkpoint | 1 | 1 |
| trifluoperazine | GO:0007049 cell cycle | 0.875 | 1 |
| trifluoperazine | GO:0008283 cell population proliferation (viability) | 0.7 | 1 |
| trifluoperazine | GO:0071456 cellular response to hypoxia | 0.3333 | 0 |
| trifluoperazine | GO:0001525 angiogenesis | 0.2857 | 0 |
| trifluoperazine | GO:0008283 cell population proliferation | 0.25 | 0 |
| trifluoperazine | GO:0006954 inflammatory response | 0.2 | 0 |
| trifluoperazine | GO:0008219 cell death | 0.0625 | 0 |
| trifluoperazine | GO:0006096 glycolytic process | 0 | 0 |
| trifluoperazine | GO:0016477 cell migration | 0 | 0 |
| trifluoperazine | GO:0001837 epithelial to mesenchymal transition | 0 | 0 |
| trifluoperazine | GO:0002418 immune response to tumor cell | 0 | 0 |
| trifluoperazine | GO:0010833 telomere maintenance via telomere lengthening | 0 | 0 |
| trifluoperazine | GO:0001570 vasculogenesis | 0 | 0 |
| trifluoperazine | GO:0007155 cell adhesion | 0 | 0 |
| trifluoperazine | GO:0016049 cell growth | 0 | 0 |
| trifluoperazine | GO:0006915 apoptotic process | 0 | 0 |
| Drug (INN) |
Cancer Type | Indication Score (Range: 0~1) |
Cancer Drug or Not (Positive indication: 1) |
Novel Positives (Novel candidate: 1) |
|---|---|---|---|---|
| trifluoperazine | Cancer(general) | 0.6236 | 0 | - |